Cancer of Lung
22
1
4
10
Key Insights
Highlights
Success Rate
77% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.6%
3 terminated out of 22 trials
76.9%
-9.6% vs benchmark
0%
0 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (22)
Real-time Activity Monitoring to Prevent Admissions During RadioTherapy
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Precision Lung Cancer Survivorship Care Intervention
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Real-time Motion Management During Prostate and Lung Radiotherapy
Impact of Psychological Stress on Treatment Response and Prognosis in Lung Cancer Patients
High Intensity Aerobic Exercise Training and Immune Cell Mobilization in Patients With Lung Cancer (HI AIM)
4D CBCT and Intrafractional Imaging for the Determination of the Most Representative 4D Simulation Planning Technique for Lung SBRT Technique Patients
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Effect of 3D-printed Reconstruction System in Size of Left DLT
Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®
MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
Changing Over Time of Ascorbic Acid After Chemotherapy
A Phase I Study of iPS Cell Generation From Patients With COPD
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
Study of Arsenic Trioxide in Small Cell Lung Cancer
NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung